Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...

Muscle ultrasound has emerged as a pivotal, non‐invasive imaging modality that offers real‐time insights into muscle structure and pathology. This technique enables both qualitative and quantitative ...

Recent research from the University of Houston College of Pharmacy identifies key mechanisms of skeletal muscle regeneration and growth of muscles following resistance exercise. It's a finding that ...

For decades, treatment of peripheral artery disease has focused almost exclusively on restoring blood flow. Now, new research ...

Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...

Researchers have made a significant finding in determining the genetic background of dilated cardiomyopathy in Dobermanns. This research helps us understand the genetic risk factors related to fatal ...

The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted. ・It added that a proactive, short-course immune modulation regimen in ...

All parents will now be offered spinal muscular atrophy screening for their newborns.